Thus, patients with RA who have a higher level of serum IgG to PPAD had less of a clinical response to bDMARDs. The investigators concluded their paper by suggesting that serum anti-PPAD IgG titers might be a useful biomarker for designing a personalized treatment strategy for RA.
You Might Also Like
Also By This Author
Lara C. Pullen, PhD, is a medical writer based in the Chicago area.
- Kobayashi T, Ito S, Kobayashi D, et al. Serum immunoglobulin G levels to porphyromonas gingivalis peptidylarginine deiminase affect clinical response to biological disease-modifying anti-rheumatic drug in rheumatoid arthritis. PLoS One. 2016 Apr 25;11(4):e0154182. doi: 10.1371/journal.pone.0154182. eCollection 2016.